No­vo Nordisk sus­pend­ed from lead­ing UK trade group over obe­si­ty mar­ket­ing 'breach'

No­vo Nordisk was slapped with a two-year sus­pen­sion from the UK phar­ma in­dus­try group, the As­so­ci­a­tion of the British Phar­ma­ceu­ti­cal In­dus­try (ABPI), on Thurs­day for cross­ing the line on its code of con­duct.

The sus­pen­sion stems from an in­ves­ti­ga­tion by the Pre­scrip­tion Med­i­cines Code of Prac­tice Au­thor­i­ty (PM­C­PA), which over­sees the com­plaints pro­ce­dure of the ABPI Code, over a LinkedIn post pro­mot­ing a “free weight man­age­ment course” by a third-par­ty provider that was sup­port­ed by No­vo Nordisk.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER